This study investigated the effect of a single oral ingestion of alpha-linolenic acid-enriched diacylglycerol (ALA-DAG) on postprandial serum triglyceride (TG) levels. A randomized, double-blind, controlled, crossover study was performed in subjects with normal or moderately high fasting serum TG levels. Subjects ingested 0.00 g [control: triacylglycerol; TAG (rapeseed oil)], 1.25 g (1.25-g: mixture of 1.25 g ALA-DAG and 1.25 g TAG), or 2.50 g (2.50 g) of ALA-DAG in random order with a 6-d washout period. Serum TG levels were evaluated in the fasting state, and at 2, 3, 4, and 6 h after the test meal. Thirty-eight subjects completed the study and were defined as the per protocol set. As the primary outcome, postprandial serum TG levels were significantly lower in the 2.50-g treatment compared with the control. The TG level did not differ significantly between the 1.25-g and control. The suppressive effect of ALA-DAG on the serum TG level correlated significantly with the body mass index and fasting insulin level. ALA-DAG at a dose of 2.50 g had greater effects on serum TG and apolipoprotein B levels in subjects with a higher body mass index ($25 kg/m 2 ) and higher fasting serum insulin levels (.10 mU/mL). Our findings suggest that ingesting 2.50 g ALA-DAG suppresses the postprandial serum TG level in people with normal and moderately high fasting serum TG levels, presumably as a result of poor reesterification of dietary fat into TG in the intestinal mucosa.
eases are caused by the progression of arteriosclerosis. The Vital Statistics in Japan of 2013 (2) indicated that heart disease and cerebrovascular disease accounted for more than 30% of the total causes of death in Japan -comparable with the percentage of death caused by malignant neoplasm.
Hypertriglyceridemia is an independent factor for coronary artery disease (3) , and postprandial hypertriglyceridemia is highly correlated with ischemic heart disease, particularly myocardial infarction precipitated by coronary artery disease (4, 5) . Excessive intake of saturated fatty acids and other types of fat is considered a factor in hypertriglyceridemia, and therefore prevention and improvement by changing the diet is important. Diacylglycerol (DAG), which is widely present in nature and has a long history of human consumption, occurs in two isoforms, 1,2 (or 2,3)-diacyl-sn-glycerol (1,2-DAG) and 1,3-diacyl-sn-glycerol (1, . In most natural edible oils and manufactured DAG oil, ~70% (w/w) of the DAG is present as the 1,3-isoform which has different characteristics from triacylglycerol (TAG) in the digestion and absorption processes in the small intestine and the subsequent TAG synthesis pathway (6) (7) (8) . DAG ingestion inhibits the increase in postprandial blood triglyceride (TG) levels in cases of mild hyperlipidemia (9, 10) , insulin resistance (11) and abnormal glucose tolerance (12) . It was reported that the minimum effective dose was 2.73 g of DAG compared to general edible oils in mild hyperlipidemia (13) . The fatty acid composition of the DAG and TAG used in these reports was the same, and the inhibitory effects on the increase in blood TG are thought to be due to the difference in the DAG structure.
Alpha-linolenic acid (ALA) is easily utilized as energy in animals (14, 15) and humans (16) compared to other fatty acids, such as stearic, oleic, and linoleic acids. Therefore, DAG containing mainly ALA (ALA-DAG) is expected to increase the fat oxidation rate compared to DAG mainly containing other fatty acids, and to induce visceral fat reduction in an animal model (17) and humans (18, 19) . The effect of ALA-DAG on postprandial blood TG levels, however, has not been investigated. Additionally, the effect of a lower dose (,2.73 g) of DAG E-mail: yamanaka.nami2@kao.co.jp on blood TG levels is unclear.
Therefore, in the present study, ALA-DAG was administered at a dose of 0.00, 1.25, or 2.50 g to subjects with high fasting blood TG levels to determine the minimum effective dose of ALA-DAG to suppress postprandial serum triglyceride (TG) levels.
MATERIALS AND METHODS
Subjects. Study subjects that were screened and provided written informed consent, fulfilled the inclusion criteria, and did not fulfill the exclusion criteria were enrolled in the study. Inclusion criteria were male and female between 35 and 64 y of age with fasting blood TG levels of 120 to 199 mg/dL, and a body mass index (BMI) of 23 to less than 30 kg/m 2 . Exclusion criteria included chronic disease; taking medicine affecting glucose metabolism, fat metabolism, or blood pressure; surgery for disease or injury within 2 mo before the study; allergic symptoms to the ingredients in the test diets; regular consumption of Food with Health Claims; a feeling of unwellness or adverse physical effects from blood collection; donation of 200 mL or more of blood within 1 mo before the study; heavy smoking ($21 cigarettes a day); being a shift-worker; business trip or travel planned for 6 consecutive days or more during the study period; inability to record a diet for 9 d (3 d33 times); lack of consent to view past medical records; plan to participate in another clinical study during the study period; planned pregnancy or lactation during the study period; and unsuitability as judged by the physician in charge based on medical exams or other factors.
The sample size was determined based on preliminary examination conducted prior to this study (preliminary examination results have not yet been disclosed). In the preliminary examination, an inhibitory effect on an increase in postprandial serum TG levels was observed in the ALA-DAG 2.50-g treatment compared to TAG in 16 subjects. The target sample size needed to detect statistical significance was calculated based on the preliminary results with an alpha error rate of 5% and a beta error rate of 20% was 34 cases, and therefore set to at least 40 people.
Test diets. ALA-DAG was prepared using the method reported by Watanabe et al. (20) , from flaxseed oil (Summit Oil Corporation, Chiba, Japan) and rapeseed oil (The Nisshin OilliO Group, Ltd., Tokyo, Japan) using equipment owned by Kao Corporation (Tokyo, Japan). The w/w ratio of 1,3-DAG and 1,2-DAG in ALA-DAG was approximately 2 : 1. The control TAG was a rapeseed oil (produced by The Nisshin OilliO Group, Ltd.). The composition of the test oils is shown in Table 1 .
The ALA-DAG preparation was mixed with rapeseed oil, antioxidants, and emulsifying agents to produce a cooking oil for heating. The test shortbread was prepared for accurate and certain ingestion of ALA-DAG or TAG and contained the cooking oil, hard flour, soft flour, superfine sugar, salt, egg, pullulan, and water. The test diets comprised the shortbread administered together with a yogurt product (Bulgaria Yogurt, 0% fat, Meiji Dairies Corporation, Tokyo, Japan) and a dairy product (low-fat milk, Yotsuba Milk Products Co., Ltd., Hokkaido, Japan). Total energy of the test diets was 467 kcal; P (protein) : F (fat) : C (carbohydrate)515.8 : 27.8 : 55.1 as the energy ratio.
Study design. The study was a randomized, doubleblind, controlled, crossover study. Subjects were administered a single dose of the test diet containing 0.00 g (control), 1.25 g, or 2.50 g ALA-DAG in random order with a 6-d washout period. Changes in the serum TG level were observed during fasting, and at 2, 3, 4, and 6 h after ingesting the test diets. Subjects recorded their lifestyles, including diets and activities, for 3 d prior to the study, and a registered dietitian used nutritional calculation software (Healthy Maker Pro 501 R8, nutritional counseling version, Mushroomsoft Co., Ltd., Okayama, Japan) to calculate the nutritional level. Moderate and intense activity and consumption of alcohol were prohibited, and the subjects ingested the identical diet for their evening meal by 9:00 pm on the day before the study. On the day of the study, the subjects were prohibited from consuming any foods or drinks and from smoking after waking, and blood samples were collected after at least 12 h of fasting, and at 2, 3, 4, and 6 h after ingesting the test diets.
The subjects were prohibited from ingesting any medications, Food for Specified Health Uses, Foods with Functional Claims, nutritional food supplements, supplements, or other substances that could affect this study during the study period, including the washout periods. The subjects were also instructed to avoid excessive eating and drinking, and to maintain their usual level of diet, exercise, and other lifestyle habits.
This study was conducted in accordance with the Declaration of Helsinki (2013), and with the approval of the Oriental Ueno Health Center Ethics Committee. The study protocol was registered with the University Hospital Medical Information Network (UMIN) Center (UMIN-CTR, http://www.umin.ac.jp/ctr/index-j. Analysis of blood samples. Blood samples were centrifuged at 1,500 3g for 15 min at 4˚C, after sitting at room temperature for 15 min; serum samples for measuring TG, lipoprotein fraction, insulin, free fatty acids, and ketone body fraction were analyzed by Hoken Kagaku Kenkyujo Co., Ltd. (Kanagawa, Japan), and serum samples for measuring apolipoprotein B-48 (ApoB48) were analyzed by Kao Corporation using enzyme-linked immunosorbent assay (ELISA) kits, according to the kit instructions. Blood samples were collected in P800 blood collection tubes (Becton Dickinson Japan, Tokyo, Japan) and then centrifuged at 1,500 3g for 15 min at 4˚C, and plasma samples for measuring total glucosedependent insulinotropic polypeptide (total GIP) and active glucagon-like peptide-1 (active GLP-1) were analyzed by Kao Corporation using ELISA kits, according to the kit instructions. Blinded conditions were maintained during the measurements. The kits used in the analysis were purchased from Shibayagi Co., Ltd. (Gunma, Japan) for ApoB48, from Merck Millipore Co., Ltd. (Danvers, MA) for total GIP, and from Immuno-Biological Laboratories Co., Ltd. (Gunma, Japan) for active GLP-1.
Statistical analysis. Statistical analysis was performed on all cases that were predetermined to be included in analysis, except for cases deemed as outliers according to the Smirnov-Grubbs outlier test; cases in which serum TG, which normally rises 2 to 4 h after eating, decreased (cases in which it was suspected that the subject visited the clinic after insufficient fasting); or cases thought to be appropriate for exclusion from analysis due to lifestyle and food habits by the physician in charge. Cases in which the subject violated the study protocol or did not complete the study were also excluded.
The basic statistical measures (mean level, standard deviation, standard error, maximum level, median level, minimum level, 95% confidence interval, 25th percentile, and 75th percentile) were calculated for the main evaluation items, secondary evaluation items, and other evaluation items, for the actual level at each point of measurement, the amount of change from the initial level (Dlevel), and area under the curve (AUC) for the period of time until each measurement, incremental AUC (iAUC), mean level, Cmax, and change in Cmax (DCmax). Graphs of calculated data and descriptions show the mean level6standard error.
The Kolmogorov-Smirnov normality test was performed, and when the distribution was not normal the analysis was performed after logarithmic transformation. Dunnett's test was performed to compare the three treatments, and the Friedman test was performed in cases in which logarithmic transformation was not possible. This study was performed under the hypothesis that ingestion of 2.50 g ALA-DAG would inhibit the increase in postprandial serum TG levels, compared to the control. A study of a half-dose (the 1.25-g) was performed as an exploratory investigation. Therefore, comparison between the 2.50 g and control was also performed without consideration of multiplicity. A paired t test was performed to compare the two treatments, and analysis was performed by logarithmic transformation when the distribution was not normal. The Wilcoxon signed rank test was performed when logarithmic transformation was not possible.
Statistical analysis software (SPSS Ver. 19, IBM Japan, Tokyo, Japan) was used to test for significant differences. A p value of less than 0.05 was considered statistically significant.
RESULTS

Subjects
Forty-eight people who met the inclusion criteria were registered as subjects (29 male, 19 female). Forty-six subjects completed the study and two dropped out of the study: one who stopped the test due to feeling ill after the fasting blood draw (before ingesting the test diets) during the first test and did not complete all three tests, and one who could not participate in all three tests due to personal reasons. Of the 46 subjects that completed the study, 4 subjects did not meet the inclusion criteria for fasting TG levels (120-199 mg/dL) in all three tests, and 4 subjects were excluded from the analysis according to the study protocol because the serum TG level decreased from the fasting state to the postprandial state, leaving a subject group comprising 38 people who met the study protocol requirements (per protocol set, PPS). The characteristics of the PPS samples are shown in Table 2 .
Diet analysis
Energy intake, protein, fat, and carbohydrate intake during the 3 d prior to each test were not significantly different among the study treatments.
Primary endpoint (change in postprandial serum TG)
There was no significant difference in the initial TG values among the study treatments (control, 1.25-g, and 2.50-g treatments: 15867.7, 16968.1, and 16168.7 mg/dL, respectively). The postprandial serum TG level was significantly lower in the 2.50-g treatment at the 3-h point compared to the control when assessed by Dunnett's test (Fig. 1A) , but the iAUC was not significantly different (Fig. 1B) . The suppressive effects of 2.50 g ALA-DAG on the iAUC of the postprandial serum TG level was significantly correlated with the BMI (Fig. 2A) and fasting serum insulin level (Fig. 2B) . BMI was also significantly correlated with the fasting serum insulin level (R50.441, p,0.01, data not shown). In the stratified analysis, subjects in the 2.50-g treatment with a BMI 25 kg/m 2 or higher, which is categorized as obesity in Japan, had significantly lower postprandial serum TG levels at the 2, 3, and 4-h points (Fig. 3A) and a smaller iAUC (Fig. 3B) . Additionally, in subjects with an abnormal fasting insulin level (.10 mU/mL), the postprandial serum TG level was significantly decreased at the 3 and 4-h points in the 2.50-g treatment (Fig. 3C) . The iAUC also tended to decrease (Fig. 3D) . The ALA-DAG effect, however, did not significantly correlate with the other factors, including the fasting serum TG level (data not shown).
In the two-treatment comparison between the 2.50-g and control without consideration of multiplicity (paired t-test or Wilcoxon signed rank test), the TG levels at the 2 and 3-h points and the iAUC were significantly decreased in the 2.50-g treatment compared with the control in the overall PPS samples (data not shown).
Secondary endpoint (change in postprandial serum ApoB48)
The initial ApoB48 values were not significantly different among the control, 1.25-g, and 2.50-g treatments (9.660.8, 10.861.1, and 10.860.8 mg/dL, respectively). Although no significant differences in ApoB48 were detected among the treatments in the PPS samples ( Fig. 4A and B) , the decrease in ApoB48 at the 3-h time-point in the 2.50-g treatment was significant when analyzed in subjects with a BMI of at least 25 kg/ m 2 by Dunnett's test (Fig. 4C) . The decrease in iAUC was not significant, even when analyzed in subjects with a BMI of at least 25 kg/m 2 by Dunnett's test (Fig. 4D ). ApoB48 was also not significantly different among the treatments in subjects with abnormal fasting serum insulin levels higher than 10 mU/mL (data not shown).
Other blood parameters
None of the other parameters measured in this study (lipoprotein fraction, insulin, free fatty acids, ketone body fraction, total GIP, and active GLP-1) were significantly different among the treatments (data not shown).
DISCUSSION
In the present study, we compared the effects of different dosages of ALA-DAG on postprandial serum TG levels. Ingestion of 2.50 g ALA-DAG suppressed the increase in postprandial serum TG levels compared to ingestion of the control oil (Figs. 1A and 3) . Ingestion of 1.25 g ALA-DAG did not have a significant suppressive effect on postprandial TG levels, suggesting that 1.25 g ALA-DAG-half the dose that provides a visceral fat decreasing effect-is not sufficient to suppress the postprandial serum TG level.
Saito et al. (11) reported that postprandial serum TG levels are significantly suppressed by administering 2.7 g DAG (mainly containing oleic acid and linoleic acid) in 10 g of fat. Although the difference between the report by Saito et al. (11) and the present study is the type of fatty acids bound to DAG, the dosage of ALA-DAG was similar. Therefore, the suppressive effect on postprandial serum TG levels observed in this study was presumably due more to the contribution of the DAG structure, predominantly 1,3-DAG, which leads to poor re-esterification of dietary fat into TG in the intestinal mucosa, than to the contribution of the types of fatty acids. On the other hand, TG-rich lipoproteins are poorly formed after a DAG diet compared to a TAG diet (21) . In addition, chylomicrons are rapidly cleared after ingesting DAG compared to TAG (22) . These mechanisms are potentially different depending on the type of fatty acids bound to DAG. Therefore, additional studies are required to explain the relationship between DAG and the type of fatty acids bound to it. Moreover, the type of fatty acids comprising the fat and their binding sites (i.e., the sn positions) may also affect the increase in postprandial serum TG levels (23) . Fatty acids comprising DAG and the binding sites of those fatty acids could have different effects on postprandial serum TG. ApoB48 is an indicator of chylomicron quantity, but our observation did not reveal an obvious effect of ALA-DAG on ApoB48 (Fig. 4) . ALA-DAG may have more of an effect on the size, rather than on the number, of chylomicron particles. Further studies are required to investigate the relationship between the DAG structure and fatty acid composition.
The TG-lowering effect of ALA-DAG correlated significantly with both BMI and insulin (Fig. 2) . Moreover, the effect was more pronounced in obese subjects with a BMI of at least 25 kg/m 2 than in the overall PPS analysis, and similar to that in subjects with higher insulin levels (.10 mU/mL). BMI was significantly correlated with insulin levels, but we were not able to determine which factor was directly associated with the ALA-DAG effect. Nevertheless, an effect of ALA-DAG to decrease visceral fat in obese people has been reported (18, 19) , and we presume that this TG-lowering effect is most likely related to the anti-obesity effect. Moreover, the TGlowering effect of DAG is readily expressed in cases of insulin resistance and glucose tolerance abnormalities (12, 13) , and thus it is possible that the effects of ALA-DAG are more easily detected in cases of an increased insulin level. A high insulin level is likely to be induced by obesity (24) , and the concomitant insulin resistance may be associated with postprandial hypertriglyceridemia due to lower lipoprotein lipase activity and the hydrolysis rate of chylomicron remnant (25) . DAG was reported to induce rapid clearance of remnants as well as chylomicrons (21) , suggesting that improved clearance of chylomicron remnants by ALA-DAG could account for the clear effect in subjects with high BMI and insulin in this study.
A limitation of the present study is that fatty acid compositions differed among the test oils (Table 1) . Therefore, we cannot conclude whether the suppressive effect of ALA-DAG on the postprandial serum TG level is associated with the DAG structure, type of fatty acid bound to DAG, or synergistic actions.
Conclusion
Our observation suggests that ingesting 2.50 g ALA-DAG has suppressive effects on the postprandial serum TG level in people with normal and moderately high fasting serum TG levels, presumably due to poor re-esterification of dietary fat into TG in the intestinal mucosa.
